SCHEMBL4875911

SCHEMBL4875911

C[SiH](C)Oc1c(C(=O)Cl)cc(OCc2ccccc2)c(C(C)(C)C)c1C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 5/20 0.42
RXRB P28702 4/20 0.42
RXRG P48443 3/20 0.42
GLRA1 P23415 1/20 0.41
MCL1 Q07820 1/20 0.38
FOLH1 Q04609 1/20 0.38
SMPD1 P17405 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PTGER1 P34995 1/20 0.37
HPGD P15428 1/20 0.36
LRRK2 Q5S007 1/20 0.36
BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4874857 0.91 RXRA (0.46) RXRARXRBRXRGMCL1FOLH1
SCHEMBL4437175 0.71 RXRA (0.52) RXRARXRBRXRGGLRA1MCL1
SCHEMBL21327456 0.70 LRRK2 (0.57) GLRA1MCL1FOLH1SMPD1HDAC1
SCHEMBL9201143 0.69 FOLH1 (0.52) RXRARXRBRXRGMCL1FOLH1
SCHEMBL341109 0.68 SGMS2 (0.62) FOLH1MAPTL3MBTL1PTGER1
SCHEMBL9336507 0.68 MAPT (0.63) RXRARXRBRXRGGLRA1MCL1
SCHEMBL13932500 0.68 GLRA1 (0.65) GLRA1HPGD
SCHEMBL4468346 0.68 GLRA1 (0.57) GLRA1MCL1FOLH1MAPTCYP2C9
SCHEMBL21327204 0.67 MCL1 (0.54) RXRARXRBRXRGGLRA1MCL1
SCHEMBL13819477 0.67 MCL1 (0.54) GLRA1MCL1FOLH1MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070850-A1 GALLOTANNINS AND ELLIGITANNINS AS REGULATORS OF CYTOKINE RELEASE THE PENN STATE RESEARCH FOUNDATION (US) 2008-03-20 US disclosed
US-7288273-B1 Gallotannins and ellagitannins as regulators of cytokine release THE PENN STATE RESEARCH FOUNDATION (US) 2007-10-30 US disclosed
EP-1232169-A1 GALLOTANNINS AND ELLAGITANNINS AS REGULATORS OF CYTOKINE RELEASE THE PENN STATE RESEARCH FOUNDATION (US) 2002-08-21 EP disclosed
WO-2001036436-A1 GALLOTANNINS AND ELLAGITANNINS AS REGULATORS OF CYTOKINE RELEASE THE PENN STATE RESEARCH FOUNDATION (US) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070850-A1 GALLOTANNINS AND ELLIGITANNINS AS REGULATORS OF CYTOKINE RELEASE IL2, IL6, TNF RXRA 4456/4885RXRB 4276/4885RXRG 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.